143 related articles for article (PubMed ID: 35114276)
21. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function.
Heideman MR; Wilting RH; Yanover E; Velds A; de Jong J; Kerkhoven RM; Jacobs H; Wessels LF; Dannenberg JH
Blood; 2013 Mar; 121(11):2038-50. PubMed ID: 23327920
[TBL] [Abstract][Full Text] [Related]
22.
Ito K; Otani S; Date Y
Cells; 2023 Apr; 12(8):. PubMed ID: 37190031
[TBL] [Abstract][Full Text] [Related]
23. Runx transcription factors repress human and murine c-Myc expression in a DNA-binding and C-terminally dependent manner.
Jacobs PT; Cao L; Samon JB; Kane CA; Hedblom EE; Bowcock A; Telfer JC
PLoS One; 2013; 8(7):e69083. PubMed ID: 23874874
[TBL] [Abstract][Full Text] [Related]
24. A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy.
Huang X; Zhang Y; Tang Y; Butler N; Kim J; Guessous F; Schiff D; Mandell J; Abounader R
Neoplasia; 2013 Aug; 15(8):952-65. PubMed ID: 23908595
[TBL] [Abstract][Full Text] [Related]
25. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.
Kelly GL; Grabow S; Glaser SP; Fitzsimmons L; Aubrey BJ; Okamoto T; Valente LJ; Robati M; Tai L; Fairlie WD; Lee EF; Lindstrom MS; Wiman KG; Huang DC; Bouillet P; Rowe M; Rickinson AB; Herold MJ; Strasser A
Genes Dev; 2014 Jan; 28(1):58-70. PubMed ID: 24395247
[TBL] [Abstract][Full Text] [Related]
26. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
27. Hipk2 cooperates with p53 to suppress γ-ray radiation-induced mouse thymic lymphoma.
Mao JH; Wu D; Kim IJ; Kang HC; Wei G; Climent J; Kumar A; Pelorosso FG; DelRosario R; Huang EJ; Balmain A
Oncogene; 2012 Mar; 31(9):1176-80. PubMed ID: 21785465
[TBL] [Abstract][Full Text] [Related]
28. Expression profiling reveals transcriptional regulation by Fbxw7/mTOR pathway in radiation-induced mouse thymic lymphomas.
Snijders AM; Liu Y; Su L; Huang Y; Mao JH
Oncotarget; 2015 Dec; 6(42):44794-805. PubMed ID: 26575021
[TBL] [Abstract][Full Text] [Related]
29. Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad.
Frenzel A; Labi V; Chmelewskij W; Ploner C; Geley S; Fiegl H; Tzankov A; Villunger A
Blood; 2010 Feb; 115(5):995-1005. PubMed ID: 19965635
[TBL] [Abstract][Full Text] [Related]
30. Regulation of the Arf tumor suppressor in Emicro-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis.
Bertwistle D; Sherr CJ
Blood; 2007 Jan; 109(2):792-4. PubMed ID: 16968893
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome.
Yokomizo-Nakano T; Kubota S; Bai J; Hamashima A; Morii M; Sun Y; Katagiri S; Iimori M; Kanai A; Tanaka D; Oshima M; Harada Y; Ohyashiki K; Iwama A; Harada H; Osato M; Sashida G
Cancer Res; 2020 Jun; 80(12):2523-2536. PubMed ID: 32341038
[TBL] [Abstract][Full Text] [Related]
32. Osteoblast-specific inactivation of p53 results in locally increased bone formation.
Liao N; Koehne T; Tuckermann J; Triviai I; Amling M; David JP; Schinke T; Luther J
PLoS One; 2021; 16(11):e0249894. PubMed ID: 34793446
[TBL] [Abstract][Full Text] [Related]
33. Expression of RUNX1-JAK2 in Human Induced Pluripotent Stem Cell-Derived Hematopoietic Cells Activates the JAK-STAT and MYC Pathways.
Fortschegger K; Husa AM; Schinnerl D; Nebral K; Strehl S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299194
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC.
Goga A; Yang D; Tward AD; Morgan DO; Bishop JM
Nat Med; 2007 Jul; 13(7):820-7. PubMed ID: 17589519
[TBL] [Abstract][Full Text] [Related]
35. c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis.
Feng YC; Liu XY; Teng L; Ji Q; Wu Y; Li JM; Gao W; Zhang YY; La T; Tabatabaee H; Yan XG; Jamaluddin MFB; Zhang D; Guo ST; Scott RJ; Liu T; Thorne RF; Zhang XD; Jin L
Nat Commun; 2020 Oct; 11(1):4980. PubMed ID: 33020477
[TBL] [Abstract][Full Text] [Related]
36. The RUNX Genes as Conditional Oncogenes: Insights from Retroviral Targeting and Mouse Models.
Neil JC; Gilroy K; Borland G; Hay J; Terry A; Kilbey A
Adv Exp Med Biol; 2017; 962():247-264. PubMed ID: 28299662
[TBL] [Abstract][Full Text] [Related]
37. MiR-467a is upregulated in radiation-induced mouse thymic lymphomas and regulates apoptosis by targeting Fas and Bax.
Gao F; Chen S; Sun M; Mitchel RE; Li B; Chu Z; Cai J; Liu C
Int J Biol Sci; 2015; 11(1):109-21. PubMed ID: 25552935
[TBL] [Abstract][Full Text] [Related]
38. Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma.
Wang Z; Zheng Y; Park HJ; Li J; Carr JR; Chen YJ; Kiefer MM; Kopanja D; Bagchi S; Tyner AL; Raychaudhuri P
Mol Cancer Ther; 2013 May; 12(5):759-67. PubMed ID: 23427295
[TBL] [Abstract][Full Text] [Related]
39. Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs.
Happo L; Phipson B; Smyth GK; Strasser A; Scott CL
Cell Death Dis; 2012 May; 3(5):e306. PubMed ID: 22573037
[TBL] [Abstract][Full Text] [Related]
40. p53 and p73 in suppression of Myc-driven lymphomagenesis.
Griesmann H; Schlereth K; Krause M; Samans B; Stiewe T
Int J Cancer; 2009 Jan; 124(2):502-6. PubMed ID: 18942718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
